Galectin Therapeutics Inc.
- GALT
- NASDAQ
- Biotechnology
- Fibrosis/Cancer Drugs
- Clinical-Stage Biopharma
$3.50
Today −3.45%Quote Oct 19, 2026, 08:00 PM UTC
−10.03%over the last month
Max drawdown −15.5%From 1-month high −15.5%3 months −9.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
9
Market value
$352.5M
Quote Oct 19
Analyst target
$11.00
+214.7% from here
Floor
$3.48
0.3% below price
Resistance
$3.54
1.2% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GALTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free